Showing results (411-420 of 523) with videos related to
Sort By:
Pageof 53
The Oncologist|May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.EJNMMI Research|August 1, 2020
18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI dataFlorent L Besson, Brice Fernandez, Sylvain Faure, et al.British Journal of Cancer|December 14, 2023
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trialSophie Postel-Vinay, Juan Coves, Matthieu Texier, et al.European Journal of Cancer (Oxford, England : 1990)|May 11, 2024
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive reviewArthur Géraud, Thomas Hueso, Ariane Laparra, et al.British Journal of Cancer|September 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosisAbderaouf Hamza, Pierre Gestraud, Maryam Karimi, et al.European Journal of Cancer (Oxford, England : 1990)|April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE studyAlexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2015
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II StudyBenjamin Besse, Sylvestre Le Moulec, Julien Mazières, et al.The Journal of Pathology|September 27, 2024
DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymomaMehdi Latiri, Mohamed Belhocine, Charlotte Smith, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2019
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung CancerAlice T Shaw, Benjamin J Solomon, Benjamin Besse, et al.Nature Medicine|May 15, 2020
Caring for patients with cancer in the COVID-19 eraJoris van de Haar, Louisa R Hoes, Charlotte E Coles, et al.Pageof 53